PI3K mutations are identified in 10-20% mCRC in exon 9 or exon 20 and lead to constitutive activation of the p110a protein kinase and its downstream pathway, which promotes tumor cell proliferation and survival (168, 169). The gene discussed is PIK3CA; the disease is neoplasm.